Fragile X syndrome: an update on developing treatment modalities
Aileen Healy1, Roger Rush, Timothy Ocain
1Seaside Therapeutics, 840 Memorial Drive, Cambridge, Masssachusetts 02139, USA.
ACS Chemical Neuroscience
|August 4, 2012
Summary
Intellectual disability (ID) was once considered untreatable, but recent scientific progress suggests it may now be manageable. Pharmaceutical therapies for Fragile X syndrome (FXS) could pave the way for treating other neurodevelopmental disorders.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Intellectual disability (ID) is typically viewed as a permanent condition.
- Current treatments focus on symptom management, not cognitive improvement.
- Recent scientific breakthroughs offer new hope for treating ID.
Purpose of the Study:
- To explore the potential for treating intellectual disability (ID).
- To highlight the significance of pharmaceutical therapies for Fragile X syndrome (FXS).
- To establish a new paradigm for central nervous system (CNS) drug discovery in neurodevelopmental disorders.
Main Methods:
- Review of recent scientific advancements in ID research.
- Analysis of emerging pharmaceutical targets for neurodevelopmental disorders.
- Evaluation of Fragile X syndrome (FXS) as a model for CNS drug development.
Main Results:
- Scientific advancements suggest ID may become a treatable condition.
- Targeted pharmaceutical therapies for FXS show promise.
- FXS therapies could serve as a benchmark for future CNS drug discovery.
Conclusions:
- Intellectual disability (ID) may transition from an immutable condition to a treatable one.
- Fragile X syndrome (FXS) therapies represent a significant step forward in neurodevelopmental disorder treatment.
- This approach could revolutionize drug discovery for central nervous system (CNS) disorders.
Keywords:
Fragile X syndromefragile X mental retardation genefragile X mental retardation proteinmetabotropic glutamate receptor 5γ-aminobutyric acidMore Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
10:58TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism
Published on: December 28, 2010
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:43Sex-linked Disorders
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
01:19X-linked Traits
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...